Chronic pulmonary aspergillosis (CPA) affects individuals with non-systemic or mildly systemic immunodepression or altered pulmonary integrity due to underlying disease. It has been reported with a variety of clinical and radiological patterns. The condition should be distinguished from simple aspergilloma and allergic bronchopulmonary aspergillosis as well as invasive aspergillosis in severely immunocompromised patients. CPA generally requires long-term antifungal treatment and surgery may be considered. Life-threatening haemoptysis may be prevented by bronchial arteriography with embolisation. However, currently there are no documented treatment recommendations for CPA. This review provides an up-to-date practical overview of this condition, including a comprehensive update on diagnosis and management.

Journal Section:
Editor's choice
Keywords:
Chronic pulmonary aspergillosis, Aspergilloma, Antifungal treatment
1.
Knutsen AP, Slavin RG: Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis. Clin Dev Immunol 2011;843-763.
[PubMed]
https://doi.org/10.1155/2011/843763
2.
Kousha M, Tadi R, Soubani AO: Pulmonary aspergillosis: a clinical review. Eur Respir Rev 2011;20:156-174.
[PubMed]
https://doi.org/10.1183/09059180.00001011
3.
Denning DW, Riniotis K, Dobrashian R, Sambatakou H: Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change and review. Clin Infect Dis 2003;37(suppl 3): S265-S280.
[PubMed]
https://doi.org/10.1086/376526
4.
Vlahakis NE, Aksamit TR: Diagnosis and treatment of allergic bronchopulmonary aspergillosis. Mayo Clin Proc 2001;76:930-938.
[PubMed]
https://doi.org/10.4065/76.9.930
5.
Soubani AO, Chandrasekar PH: The clinical spectrum of pulmonary aspergillosis. Chest 2002;121:1988-1999.
[PubMed]
https://doi.org/10.1378/chest.121.6.1988
6.
Smith NL, Denning DW: Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J 2011;37:865-872.
[PubMed]
https://doi.org/10.1183/09031936.00054810
7.
Sales MPU: Aspergillosis: from diagnosis to treatment (chapt 5). J Bras Pneumol 2009;35:1238-1244.
[PubMed]
https://doi.org/10.1590/S1806-37132009001200012
8.
Felton TW, Baxter C, Moore CB, Roberts SA, Hope WW, Denning DW: Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clin Infect Dis 2010;51:1383-1391.
[PubMed]
https://doi.org/10.1086/657306
9.
Park SY, Lee SO, Choi SH, Jeong JY, Sung H, Kim MN, Choi CM, Hong SB, Oh YM, Shim TS, Lim CM, Koh Y, Kim DS, Kim YS, Woo JH, Kim SH: Serum and bronchoalveolar lavage fluid galactomannan assays in patients with pulmonary aspergilloma. Clin Infect Dis 2011;52:e149-152.
[PubMed]
https://doi.org/10.1093/cid/cir027
10.
Kono Y, Tsushima K, Yamaguchi K, Kurita N, Soeda S, Fujiwara A, Sugiyama S, Togashi Y, Kasagi S, To M, To Y, Setoguchi Y: The utility of galactomannan antigen in the bronchial washing and serum for diagnosing pulmonary aspergillosis. Respir Med 2013;107:1094-1100.
[PubMed]
https://doi.org/10.1016/j.rmed.2013.04.007
11.
Izumikawa K, Yamamoto Y, Mihara T, Takazono T, Morinaga Y, Kurihara S, Nakamura S, Imamura Y, Miyazaki T, Nishino T, Tsukamoto M, Kakeya H, Yanagihara K, Mine M, Yasuoka A, Tashiro T, Kohno S: Bronchoalveolar lavage galactomannan for the diagnosis of chronic pulmonary aspergillosis. Med Mycol 2012;50:811-817.
[PubMed]
https://doi.org/10.3109/13693786.2012.682228
12.
Camuset J, Nunes H, Dombret MC, Bergeron A, Henno P, Philippe B, et al: Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest 2007;131:1435-1441.
[PubMed]
https://doi.org/10.1378/chest.06-2441
13.
Parakh UK, Sinha R, Bhatnagar AK, Singh P: Chronic necrotising pulmonary aspergillosis: a rare complication in a case of silicosis. Indian J Chest Dis Allied Sci 2005;47:199-203.
[PubMed]
14.
Pena TA, Soubani AO, Samavati L: Aspergillus lung disease in patients with sarcoidosis: a case series and review of the literature. Lung 2011;189:167-172.
[PubMed]
https://doi.org/10.1007/s00408-011-9280-9
15.
Yousem SA: The histological spectrum of chronic necrotizing forms of pulmonary aspergillosis. Hum Pathol 1997;28:650-656.
[PubMed]
https://doi.org/10.1016/S0046-8177(97)90173-8
16.
Binder RE, Faling LJ, Pugatch RD, Mahasen C, Snider GL: Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity. Medicine 1982;61:109-124.
[PubMed]
https://doi.org/10.1097/00005792-198203000-00005
17.
Gefter WB, Weingrad TR, Epstein DM, Ochs RM, Miller WT: ‘Semi-invasive' pulmonary aspergillosis: a new look at the spectrum of Aspergillus infections of the lung. Radiology 1981;140:313-321.
[PubMed]
https://doi.org/10.1148/radiology.140.2.7255704
18.
Klein DL, Gamsu G: Thoracic manifestations of aspergillosis. Am J Roentgenol 1980;134:543-552.
[PubMed]
https://doi.org/10.2214/ajr.134.3.543
19.
Kim SY, Lee KS, Han J, Kim J, Kim TS, Choo SW, Kim SJ: Semi-invasive pulmonary aspergillosis: CT and pathologic findings in six patients. Am J Roentgenol 2000;174:795-798.
[PubMed]
https://doi.org/10.2214/ajr.174.3.1740795
20.
Franquet T, Müller NL, Giménez A, Guembe P, de la Torre J, Bagué S: Spectrum of pulmonary aspergillosis: histologic, clinical, and radiologic findings. Radiographics 2001;21:825-837.
[PubMed]
https://doi.org/10.1148/radiographics.21.4.g01jl03825
21.
Uffredi ML, Mangiapan G, Cadranel J, Kac G: Significance of Aspergillusfumigatus isolation from respiratory specimens of nongranulocytopenic patients. Eur J Clin Microbiol Infect Dis 2003;22:457-462.
[PubMed]
https://doi.org/10.1007/s10096-003-0970-y
22.
Zmeili OS and Soubani AO: Pulmonary aspergillosis: a clinical update. QJM 2007;100:317-334.
[PubMed]
https://doi.org/10.1093/qjmed/hcm035
23.
Ohba H, Miwa S, Shirai M, Kanai M, Eifuku T, Suda T, et al: Clinical characteristics and prognosis of chronic pulmonary aspergillosis. Respir Med 2012;106:724-729.
[PubMed]
https://doi.org/10.1016/j.rmed.2012.01.014
24.
Izumikawa K, Yamamoto Y, Mihara T, Takazono T, Morinaga Y, Kurihara S, et al: Bronchoalveolar lavage galactomannan for the diagnosis of chronic pulmonary aspergillosis. Med Mycol 2012;50:811-817.
[PubMed]
https://doi.org/10.3109/13693786.2012.682228
25.
Guitard J, Sendid B, Thorez S, Gits M, Hennequin C: Evaluation of a recombinant antigen-based enzyme immunoassay for the diagnosis of noninvasive aspergillosis. J Clin Microbiol 2012;50:762-765.
[PubMed]
https://doi.org/10.1128/JCM.01257-11
26.
Kitasato Y, Tao Y, Hoshino T, Tachibana K, Inoshima N, Yoshida M, Takata S, Okabayashi K, Kawasaki M, Iwanaga T, Aizawa H: Comparison of Aspergillus galactomannan antigen testing with a new cut-off index and Aspergillus precipitating antibody testing for the diagnosis of chronic pulmonary aspergillosis. Respirology 2009;14:701-718.
[PubMed]
https://doi.org/10.1111/j.1440-1843.2009.01548.x
27.
Greene R: The radiological spectrum of pulmonary aspergillosis. Med Mycol 2005;43:S147-S154.
[PubMed]
https://doi.org/10.1080/13693780500064771
28.
Hafeez I, Muers MF, Murphy SA, Evans EG, Barton RC, McWhinney P: Non-tuberculous mycobacterial lung infection complicated by chronic necrotising pulmonary aspergillosis. Thorax 2000;55:717-719.
[PubMed]
https://doi.org/10.1136/thorax.55.8.717
29.
Kobashi Y, Fukuda M, Yoshida K, Miyashita N, Niki Y, Oka M: Chronic necrotizing pulmonary aspergillosis as a complication of pulmonary Mycobacterium avium complex disease. Respirology 2006;11:809-813.
[PubMed]
https://doi.org/10.1111/j.1440-1843.2006.00952.x
30.
Jhun BW, Jeon K, Eom JS, Lee JH, Suh GY, Kwon OJ, Koh WJ: Clinical characteristics and treatment outcomes of chronic pulmonary aspergillosis. Med Mycol 2013;51:811-817.
[PubMed]
https://doi.org/10.3109/13693786.2013.806826
31.
Agarwal R, Vishwanath G, Agarwal AN, Garg M, Gupta D, Chakrabarti A: Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature. Mycoses 2013;56:559-570.
[PubMed]
https://doi.org/10.1111/myc.12075
32.
Al-Alawi A, Ryan CF, Flint JD, Müller NL: Aspergillus-related lung disease. Can Respir J 2005;12:377-387.
[PubMed]
33.
Philippe B, Germaud P: Aspergillus in the immunocompetent patient. Towards a new classification? Rev Mal Respir 2005;22:711-714.
[PubMed]
https://doi.org/10.1016/S0761-8425(05)85625-6
34.
Denning DW: Chronic forms of pulmonary aspergillosis. Clin Microbiol Infect 2001;7:25-31.
[PubMed]
https://doi.org/10.1111/j.1469-0691.2001.tb00006.x
35.
Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al: Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-360.
[PubMed]
https://doi.org/10.1086/525258
36.
Campbell JH, Winter JH, Richardson MD, Shankland GS, Banham SW: Treatment of pulmonary aspergilloma with itraconazole. Thorax 1991;46:839-841.
[PubMed]
https://doi.org/10.1136/thx.46.11.839
37.
Passera E, Rizzi A, Robustellini M, Rossi G, Della Pona C, Massera F, et al: Pulmonary aspergilloma: clinical aspects and surgical treatment outcome. Thorac Surg Clin 2012;22:345-361.
[PubMed]
https://doi.org/10.1016/j.thorsurg.2012.04.001
38.
Lee KH, Ryu SM, Park SM, Park HS, Lee KH, Cho SJ: A surgically treated case of chronic necrotizing aspergillosis with pleural invasion. Korean J Thorac Cardiovasc Surg 2012;45:56-59.
[PubMed]
https://doi.org/10.5090/kjtcs.2012.45.1.56
39.
Pabst S, Krüger M, Skowasch D, Zhou H, Bürmann J, Kaminski M: Pulmonary aspergillosis: therapeutic management and prognostic factors from 16 years of monocenter experience. Adv Exp Med Biol 2013;755:225-236.
[PubMed]
https://doi.org/10.1007/978-94-007-4546-9_29
40.
Saraceno JL, Phelps DT, Ferro TJ, Futerfas R, Schwartz DB: Chronic necrotizing pulmonary aspergillosis - approach to management. Chest 1997;112:541-548.
[PubMed]
https://doi.org/10.1378/chest.112.2.541
41.
Al-Shair K et al: Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis: a longitudinal analysis. Clin Infect Dis 2013;57:828-835.
[PubMed]
https://doi.org/10.1093/cid/cit411
42.
Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, et al: Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000;30:696-709.
[PubMed]
https://doi.org/10.1086/313756
43.
Endo S, Sohara Y, Murayama F, Yamaguchi T, Hasegawa T, Tezuka K, et al: Surgical outcome of pulmonary resection in chronic necrotizing pulmonary aspergillosis. Ann Thorac Surg 2001;72:889-894.
[PubMed]
https://doi.org/10.1016/S0003-4975(01)02884-3
44.
Babatasi G, Massetti M, Chapelier A, Fadel E, Macchiarini P, Khayat A, et al: Surgical treatment of pulmonary aspergilloma: current outcome. J Thorac Cardiovasc Surg 2000;19:906-912.
[PubMed]
https://doi.org/10.1016/S0022-5223(00)70085-7
45.
Ikemoto H: Medical treatment of pulmonary aspergilloma. Intern Med 2000;39:191-192.
[PubMed]
https://doi.org/10.2169/internalmedicine.39.191
46.
Chen JC, Change YL, Luh SP, Lee JM, Lee YC: Surgical treatment for pulmonary aspergilloma: a 28-year experience. Thorax 1997;52:810-813.
[PubMed]
https://doi.org/10.1136/thx.52.9.810
47.
Farid S, Mohamed S, Devbhandari M, Kneale M, Richardson M, Soon SY, Jones MT, Krysiak P, Shah R, Denning DW, Rammohan K: Results of surgery for chronic pulmonary aspergillosis, optimal antifungal therapy and proposed high risk factors for recurrence - a National Centre's experience. J Cardiothorac Surg 2013;8:180.
[PubMed]
https://doi.org/10.1186/1749-8090-8-180
48.
Bulpa P, Dive A, Sibille Y: Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J 2007;30:782-800.
[PubMed]
https://doi.org/10.1183/09031936.00062206
49.
De Beule K, De Doncker P, Cauwenbergh G, Koster M, Legendre R, Blatchford N, et al: The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982-1987). Mycoses 1988;31:476-485.
[PubMed]
https://doi.org/10.1111/j.1439-0507.1988.tb03653.x
50.
Jain LR, Denning DW: The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. Infection 2006;52:133-137.
[PubMed]
https://doi.org/10.1016/j.jinf.2005.08.022
51.
Kohno S, Izumikawa K, Ogawa K, Kurashima A, Okimoto N, Amitani R, et al: Japan Chronic Pulmonary Aspergillosis Study Group (JCPASG): Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicentre trial in Japan. J Infect 2010;61:410-418.
[PubMed]
https://doi.org/10.1016/j.jinf.2010.08.005
52.
Fujita M, Tao Y, Kajiki A, Ouchi H, Harada E, Ikegame S, et al: The clinical efficacy and safety of micafungin-itraconazole combination therapy in patients with pulmonary aspergilloma. J Infect Chemother 2012;18:668-674.
[PubMed]
https://doi.org/10.1007/s10156-012-0391-x
53.
Dupont B: Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol 1990;23:607-614.
[PubMed]
https://doi.org/10.1016/0190-9622(90)70263-H
54.
Saito T, Fujiuchi S, Tao Y, Sasaki Y, Ogawa K, Suzuki K, et al: Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan. Infection 2012;40:661-667.
[PubMed]
https://doi.org/10.1007/s15010-012-0322-x
55.
Cadranel J, Philippe B, Hennequin C, Bergeron A, Bergot E, Bourdin A, et al: Voriconazole for chronic pulmonary aspergillosis: a prospective multicentre trial. Eur J Clin Microbiol Infect Dis 2012;31:3232-3239.
[PubMed]
https://doi.org/10.1007/s10096-012-1690-y
56.
Sambatakou H, Dupont B, Lode H, Denning DW: Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med 2006;119:527.e17-e24.
[PubMed]
https://doi.org/10.1016/j.amjmed.2005.11.028
57.
Kohno S, Izumikawa K, Kakeya H, Miyazaki Y, Ogawa K, Amitani R, et al: Clinical efficacy and safety of micafungin in Japanese patients with chronic pulmonary aspergillosis: a prospective observational study. Med Mycol 2011;49:688-693.
[PubMed]
https://doi.org/10.3109/13693786.2011.561369
58.
Yoshida K, Kurashima A, Kamei K, Oritsu M, Ando T, Yamamoto T, et al: Efficacy and safety of short- and long-term treatment of itraconazole on chronic necrotizing pulmonary aspergillosis in a multicenter study. J Infect Chemother 2012;18:378-385.
[PubMed]
https://doi.org/10.1007/s10156-012-0414-7
59.
Nam HS, Jeon K, Um SW, Suh GY, Chung MP, Kim H, et al: Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases. Int J Infect Dis 2010;14:e479-e482.
[PubMed]
https://doi.org/10.1016/j.ijid.2009.07.011
60.
Tsubura E: Multicenter clinical trial of itraconazole in the treatment of pulmonary aspergilloma. Pulmonary Aspergilloma Study Group (in Japanese). Kekkaku 1997;72:557-564.
[PubMed]
61.
Escribano P, Recio S, Peláez T, González- Rivera M, Bouza E, Guinea J: In vitro acquisition of secondary azole resistance in Aspergillus fumigatus isolates after prolonged exposure to itraconazole: presence of heteroresistant populations. Antimicrob Agents Chemother 2012;56:174-178.
[PubMed]
https://doi.org/10.1128/AAC.00301-11
62.
Tashiro M, Izumikawa K, Hirano K, Ide S, Mihara T, Hosogaya N, et al: Correlation between triazole treatment history and susceptivity in clinically isolated Aspergillus fumigatus. Antimicrob Agents Chemother 2012;56:4870-4875.
[PubMed]
https://doi.org/10.1128/AAC.00514-12
63.
Cecil JA, Wenzel RP: Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections. Expert Rev Hematol 2009;2:237-254.
[PubMed]
https://doi.org/10.1586/ehm.09.13
64.
Limper AH, et al: An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011;183:96-128.
[PubMed]
https://doi.org/10.1164/rccm.2008-740ST
65.
Pfizer: Summary of Product Characteristics. Vfend (voriconazole).
66.
Izumikawa K, et al: Management of chronic pulmonary aspergillosis. Ann NY Acad Sci 2012;1272:40-48.
[PubMed]
https://doi.org/10.1111/j.1749-6632.2012.06758.x
67.
Khalil A, Parrot A, Nedelcu C, Fartoukh M, Marsault C, Carette MF: Severe hemoptysis of pulmonary arterial origin: signs and role of multidetector row CT angiography. Chest 2008;133:212-219.
[PubMed]
https://doi.org/10.1378/chest.07-1159
68.
Corr P: Management of severe hemoptysis from pulmonary aspergilloma using endovascular embolization. Cardiovasc Intervent Radiol 2006;29:807-810.
[PubMed]
https://doi.org/10.1007/s00270-005-0329-0
69.
Uflacker R, Kaemmerer A, Picon PD, Rizzon CF, Neves CM, Oliveira ES, et al: Bronchial artery embolization in the management of hemoptysis: technical aspects and long-term results. Radiology 1985;157:637-644.
[PubMed]
https://doi.org/10.1148/radiology.157.3.4059552
70.
Giron J, Poey C, Fajadet P, Sans N, Fourcade D, Senac JP, et al: CT-guided percutaneous treatment of inoperable pulmonary aspergilloma: a study of 40 cases. Eur J Radiol 1998;28:235-242.
[PubMed]
https://doi.org/10.1016/S0720-048X(97)00148-4
71.
Giron JM, Poey CG, Fajadet PP, Balagner GB, Assoun JA, Richardi GR, et al: Inoperable pulmonary aspergilloma: percutaneous CT-guided injection with glycerin and amphotericin B paste in 15 cases. Radiology 1993;188:825-827.
[PubMed]
https://doi.org/10.1148/radiology.188.3.8351356
© 2014 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2014
You do not currently have access to this content.